Talal Seddik

Clinical Associate Professor, Pediatrics - Infectious Diseases

Clinical Focus

Pediatric Infectious Diseases

Academic Appointments

Clinical Associate Professor, Pediatrics - Infectious Diseases

Administrative Appointments

Director of Pediatric Infection Prevention and Control, John Muir Health (2019 - Present)
Director of Pediatric Antimicrobial Stewardship, John Muir Health (2019 - Present)

Professional Education

Board Certification: American Board of Pediatrics, Pediatric Infectious Diseases (2019)
Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2018) CA
Board Certification: American Board of Pediatrics, Pediatrics (2015)
Residency: University of Florida at Sacred Heart Pediatric Residency (2015) FL
Medical Education: Cairo University Faculty of Medicine Office of the Registrar (2009) Egypt
Board Certification, American Board of Pediatrics (2015)
Residency, Florida State University (2015)
Internship, Florida State University (2013)
Medical Education, Cairo University School of Medicine (2009)

Contact

Academic talal@stanford.edu

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Stanford Children's Health Specialty Services 106 La Casa Via Ste 100 Walnut Creek CA 94598 Tel: (650) 721-5805 Fax: (650) 723-0864

Additional Clinical Info

Stanford Medicine Children's Health

Current Research and Scholarly Interests

Talal Seddik is a member of the Collaborative Antiviral Study Group. He is the key site investigator at the Stanford site for the following multicenter studies:

1) Enterovirus Natural History Study
Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality

This study is actively enrolling subjects

2) Acute Flaccid Myelitis (AFM) Study
A Prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors and Pathogenetic Mechanisms

This study is closed for enrollment.

3) Congenital CMV Follow up Study
A Retrospective Follow-Up Study of The Durability of Antiviral Therapy on Long-Term Hearing and Neurodevelopmental Outcomes Among Patients Treated for Congenital Cytomegalovirus
Infection as Infants or Toddlers

https://cpic.rarediseasesnetwork.org/research-study/8604

Clinical Trials

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Not Recruiting
More
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants who are between 50 and 69 years of age. This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2). Substudy A: This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation \[frozen or freeze dry powder\]) or the approved shingles vaccine intramuscularly. Participants will be assigned in 1 of 14 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit. Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years. Substudy B: This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection will be determined from Substudy A. Participants will be involved in this study for up to 5 years.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Talal Seddik
View full details
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Recruiting
More
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. * Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in. * Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose. * Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy E design: includes participants 2 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine.
Lead Sponsor
Stanford Investigators
- Talal Seddik
- Yvonne Maldonado
View full details

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Talal Seddik

Clinical Associate Professor, Pediatrics - Infectious Diseases

Stanford Investigators

Stanford Investigators

Talal Seddik

Clinical Associate Professor, Pediatrics - Infectious Diseases

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators